Search results
Results from the WOW.Com Content Network
The tobacco-specific nitrosamines are present in cigarette smoke and to a lesser degree in "smokeless" tobacco products such as dipping tobacco and chewing tobacco; additional information has shown that trace amounts of NNN and NNK have been detected in e-cigarettes. [3] They are present in trace amounts in snus. They are important carcinogens ...
Smokeless tobacco is a tobacco product that is used by means other than smoking. [1] Their use involves chewing, sniffing, or placing the product between gum and the cheek or lip. [1] Smokeless tobacco products are produced in various forms, such as chewing tobacco, snuff, snus, and dissolvable tobacco products. [2]
Nicotine gum is a chewing gum containing a small dose of nicotine polacrilex. [1] It is classified as a short-acting (also called fast-acting) form of NRT because it relieves the cravings and symptoms that occur with smoking cessation more quickly than a long-acting NRT (i.e., the nicotine patch).
U.S. Smokeless Tobacco Company The U.S. Smokeless Tobacco collection contains internal corporate documents from the U.S. Smokeless Tobacco Company, the largest manufacturer of moist snuff smokeless tobacco products in the U.S. and producer of the well-known brands, Skoal and Copenhagen. UCSF Brown & Williamson
Nicotine replacement therapy (NRT) is a medically approved way to treat people with tobacco use disorder by taking nicotine through means other than tobacco. [6] It is used to help with quitting smoking or stopping chewing tobacco. [1] [7] It increases the chance of quitting tobacco smoking by about 55%. [8]
Treatment Improvement Protocols (TIPs) are a series of best-practice manuals for the treatment of substance use and other related disorders. The TIP series is published by the Substance Abuse and Mental Health Services Administration (SAMHSA), an operational division of the U.S. Department of Health and Human Services .
The Family Smoking Prevention and Tobacco Control Act (also known as the FSPTC Act) was signed into law by President Barack Obama on June 22, 2009. This bill changed the scope of tobacco policy in the United States by giving the FDA the ability to regulate tobacco products, similar to how it has regulated food and pharmaceuticals since the passing of the Pure Food and Drug Act in 1906.
MPOWER is a policy package intended to assist in the country-level implementation of effective interventions to reduce the demand for tobacco, as ratified by the World Health Organization (WHO) Framework Convention on Tobacco Control. [1] The six evidence-based components of MPOWER are: Monitor tobacco use and prevention policies